Growth hormone-inducible transmembrane protein (GHITM)

Growth hormone-inducible transmembrane protein (GHITM) is a ubiquitously expressed mitochondrial inner membrane protein belonging to the TMBIM (BAX inhibitor motif containing) family and the BI-1 (BAX inhibitor-1) superfamily[1][5]. GHITM plays a critical role in regulating mitochondrial dynamics, maintaining cristae structure, and modulating apoptosis through control of cytochrome c release and calcium ion homeostasis[1][3][4]. It is involved in both BAX-independent maintenance of mitochondrial architecture and cross-linking of cytochrome c to the mitochondrial membrane. Overexpression of GHITM has been observed in several cancers, and its deregulation impacts mitochondrial integrity, neuronal survival, energy metabolism, and possibly the progression of aging, especially in the context of chronic viral infection[1][3][5]. GHITM is considered a potential therapeutic target, especially in oncology and neurodegenerative disease, due to its central role in mitochondrial quality control and cell survival pathways[3][4][5]. Key literature points: - Localized mainly in mitochondria, sometimes in ER, structurally defined by multiple transmembrane domains[1][5]. - Maintains mitochondrial cristae, controls cytochrome c retention/release, and regulates proton-dependent calcium efflux[1][3][4]. - Linked to tumorigenesis and overexpressed in certain cancers including breast cancer[1][5]. - Implicated in mitochondrial dysfunction-related neurodegenerative diseases and observed in transcriptomic alterations with Atxn2 and Pink1[3]. - No approved drugs or clinical biomarkers as of now; many mechanisms and interactions still under investigation[3][4].

Other names

DERP2HSPC282MICS1MY021TMBIM5PTD010Growth hormone-inducible transmembrane proteinMitochondrial morphology and cristae structure 1Dermal papilla-derived protein 2Transmembrane BAX inhibitor motif-containing protein 5